BiotechTube
Home/Pipeline/DDX3 Inhibitor (Oncology)

DDX3 Inhibitor (Oncology)

Oncology (unspecified)

DiscoveryActive

Key Facts

Indication
Oncology (unspecified)
Phase
Discovery
Status
Active
Company
Lead Discovery Siena

About Lead Discovery Siena

Lead Discovery Siena is a private, preclinical-stage biotechnology company founded in 2015 (originating from a 2012 spin-off). It leverages a multi-faceted platform combining AI/machine learning, medicinal chemistry, and biological services to advance its own drug candidates and service client programs. The company's strategy is built on fostering local and international collaborations, with a pipeline featuring promising assets in glioblastoma and broad-spectrum antivirals, alongside a proprietary Antibody Drug Conjugate (ADC) linker technology.

View full company profile

Therapeutic Areas

OncologyInfectious DiseasesPulmonary Diseases

Other Oncology (unspecified) Drugs

DrugCompanyPhase
Oncology Vaccine ProgramCHAIN BiotechPre-clinical
ARX305NovoCodex BiopharmaceuticalsPhase 1
ARX788NovoCodex BiopharmaceuticalsPhase 1
Cancer Immunotherapy NanotherapeuticFlashpoint TherapeuticsPhase 1
GRWD5769Greywolf TherapeuticsPhase 1/2
Platform-derived Program(s)Immuto ScientificDiscovery/Pre-clinical
MBT Oncology ProgramIonic PharmaceuticalsPre-clinical
ISB 2301Ichnos Glenmark InnovationPreclinical
GRC 65327Ichnos Glenmark InnovationPreclinical
Platform-Derived PipelinePhinomicsDiscovery/Pre-clinical
Lead Small-Molecule InhibitorEris BiotechPre-clinical
Orotecan™Edison OncologyPhase 1/2a